Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Marjan Cruijsen, Jacobien R. Hilberink, Walter J. F. M. van der Velden, Joop H. Jansen, Brigitte Bar, Nicolaas P. M. Schaap, Anton de Haan, Andre B. Mulder, Marco R. de Groot, Frederic Baron, Edo Vellenga, Nicole N. M. Blijlevens, Gerwin Huls
Summary: The combination of decitabine with a standard non-myeloablative conditioning regimen prior to allogeneic hematopoietic cell transplantation can effectively reduce relapse incidence in poor risk AML patients. The study demonstrated a one-year relapse rate of 23% and a one-year overall survival of 70% in this patient population.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: We retrospectively evaluated allogeneic stem cell transplant (alloSCT) outcomes of 86 adult ALL patients in complete remission (CR) who received TBI-containing reduced intensity (RIC) and myeloablative conditioning (MAC). The study found no significant difference in survival rate between the RIC and MAC groups, but the MAC group had a lower relapse rate.
LEUKEMIA & LYMPHOMA
(2023)
Article
Medicine, General & Internal
David I. Marks, Anna Castleton, Eduardo Olavarria, Maria Gilleece, Adele Fielding, George Mikhaeel, Matthew Beasley, Patricia Diez, Aimee Jackson, Andrea Hodgkinson, Mohamed Elhanied, Ronjon Chakraverty
Summary: This study examines the usage of T-cell depleted, reduced intensity conditioning (RIC) approach to haematopoietic cell transplantation (HCT) in adult patients with acute lymphoblastic leukaemia (ALL). The results show encouraging survival rates but high relapse rates, suggesting the need for more powerful conditioning approaches.
Article
Hematology
Dipenkumar Modi, Vijendra Singh, Seongho Kim, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: When comparing outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning and myeloablative conditioning regimens using thymoglobulin for GVHD prophylaxis, there was no significant difference in survival, relapse rates, or GVHD-free relapse-free survival between the two regimens. Thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with the reduced intensity conditioning regimen.
ANNALS OF HEMATOLOGY
(2021)
Article
Biophysics
Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Jiri Pavlu, Luca Castagna, Gerard Socie, Yves Chalandon, Massimo Martino, Friedrich Stolzel, Gesine Bug, Benedetto Bruno, Radovan Vrhovac, Amandine Charbonnier, Attilio Olivieri, Jacques-Olivier Bay, Herrera Arroyo, Ibrahim Yakoub-Agha, Daniele Avenoso, Andreas Neubauer, Stephanie Nguyen, Edouard Forcade, Eolia Brissot, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: The optimal conditioning regimen prior to haploidentical stem cell transplantation for acute myeloid leukemia remains uncertain. In younger patients, intensifying the conditioning from CyFluTBI to TBF may reduce relapse risk, while in older patients, the conditioning regimen does not significantly influence survival but can lower the risk of non-relapse mortality.
BONE MARROW TRANSPLANTATION
(2022)
Article
Biophysics
Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Jun Ishikawa, Keisuke Kataoka, Souichi Shiratori, Takashi Ikeda, Ken-ichi Matsuoka, Shuro Yoshida, Tadakazu Kondo, Takafumi Kimura, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: The study showed that UCB transplantation with optimal conditioning and GVHD prophylaxis had better outcomes compared to MRD and MUD transplantation, suggesting it is a highly effective treatment for mature lymphoid malignancies. This indicates that UCB transplantation might be preferred over MRD or MUD transplantation in certain settings.
BONE MARROW TRANSPLANTATION
(2022)
Review
Oncology
Rahul K. K. Nayak, Yi-Bin Chen
Summary: Allogeneic hematopoietic cell transplant is a central treatment for acute myeloid leukemia in first complete remission, but disease relapse remains a concern. Ongoing investigations are exploring maintenance therapies including targeted agents, hypomethylating agents, immunomodulatory therapies, and cellular therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Soo-Mee Bang, Jeong-Ok Lee
Summary: This study retrospectively examined the outcomes of 106 AML patients in CR1 undergoing AlloSCT with or without consolidation chemotherapy. Results showed that consolidation chemotherapy prior to AlloSCT with RIC conditioning did not negatively impact the outcomes, with longer RFS and overall survival in the consolidation group. Additionally, consolidation did not affect engraftment rates but may lead to a higher degree of chronic GVHD.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Hematology
Tommy Alfaro Moya, Jonas Mattsson, Mats Remberger, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun D. Law, Armin Gerbitz, Ivan Pasic, Igor Novitzky-Basso, Fotios V. Michelis
Summary: This retrospective analysis compared the outcomes of myeloablative (MAC) and reduced intensity conditioning (RIC) in allogenic hematopoietic cell transplantation (alloHCT) for acute myeloid leukemia (AML) in complete remission (CR). The results showed differences in nonrelapse mortality, cumulative incidence of relapse, and overall survival between the two treatment methods. However, in the subgroup analysis of matched related donor transplants, MAC was associated with superior survival. Overall, the outcomes of MAC and RIC were similar in this cohort of predominantly in vivo T-cell depleted patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Immunology
Agnieszka Tomaszewska, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, Peter Remenyi, Fabio Ciceri, Jean H. Bourhis, Patrice Chevallier, Carlos Solano, Gerard Socie, Benedetto Bruno, Alessandro Rambaldi, Luca Castagna, Nicolaus Kroger, Paolo Corradini, Boris Afanasyev, Marco Ladetto, Dietger Niederwieser, Christof Scheid, Henrik Sengeloev, Frank Kroschinsky, Ibrahim Yakoub-Agha, Helene Schoemans, Christian Koenecke, Olaf Penack, Zinaida Peric, Hildegard Greinix, Rafael F. Duarte, Grzegorz W. Basak
Summary: A retrospective analysis of 3839 adult patients with B-cell malignancies undergoing alloHCT found that adding rituximab to reduced intensity conditioning regimens did not significantly impact major transplant outcome variables. However, the lack of data on chronic GVHD in this study limits the conclusions that can be drawn.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Amandeep Salhotra, Anthony Selwyn Stein
Summary: Over the past two decades, there has been consistent improvement in the clinical outcomes of acute leukemia patients undergoing allogenic stem cell transplantation. Advances in supportive care practices, genetic testing for risk stratification, measurable residual disease assessment, and attempts to clear residual disease clones have contributed to these improvements. However, the risk of relapse post-transplant remains high for patients who do not achieve remission prior to transplant. Total body irradiation-based intensification of transplant conditioning may help overcome this risk, but previous escalation of conditioning intensity has not significantly improved overall survival due to increased nonrelapse mortality. Incorporating newer radiation techniques, such as total marrow irradiation, may safely deliver targeted doses of radiation and improve outcomes for active leukemia patients. Treatment options for post allo-HCT relapse are also discussed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Biophysics
Juergen Finke, Claudia Schmoor, Matthias Stelljes, Andreas Burchert, Peter Dreger, Ute Hegenbart, Eva-Maria Wagner-Drouet, Martin Bornhaeuser, Kristina Sohlbach, Natalie Schub, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, Olga Grishina
Summary: This study aimed to investigate the efficacy of a second allogeneic HCT using Thiotepa, Fludarabine, and Treosulfan (TFT) as conditioning therapy in patients with AML relapse > 6 months after the first allogeneic HCT. The results showed that this approach is feasible and has a high anti-leukemic efficacy, but relapse rates and non-relapse mortality remain a challenge.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ali Bazarbachi, Urpu Salmenniemi, Stephan Mielke, Patrice Chevallier, Marie Therese Rubio, Marie Balsat, Pietro Pioltelli, Anne-Lise Menard, Gerard Socie, Anne Huynh, Nicolaas Schaap, Arancha Bermudez Rodriguez, Jan J. Cornelissen, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Sebastian Giebel, Eolia Brissot, Zina Peric, Arnon Nagler, Mohamad Mohty
Summary: This study evaluated the outcomes of CNS-positive and CNS-negative adult ALL patients after allo-HCT, and found that the CNS-positive group had a higher relapse incidence, but no significant impact on LFS and OS; for CNS-positive patients, a MAC-TBI regimen showed better outcomes.
Article
Biophysics
Sebastian Giebel, Myriam Labopin, Mohamed Houhou, Denis Caillot, Juergen Finke, Didier Blaise, Nathalie Fegueux, Mark Ethell, Jan J. Cornelissen, Edouard Forcade, Ibrahim Yakoub-Agha, Federico Lussana, Johan Maertens, Jean Henri Bourhis, Pavel Jindra, Norbert Claude Gorin, Arnon Nagler, Mohamad Mohty
Summary: For elderly patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1), autologous hematopoietic cell transplantation (auto-HCT) may be considered as an alternative to reduced intensity conditioning allogeneic HCT (RIC-allo-HCT). A retrospective study compared outcomes of RIC-allo-HCT from matched sibling donors (MSD) or matched unrelated donors (MUD) with auto-HCT for patients aged 55 years or more. While the probabilities of leukemia-free survival (LFS) and overall survival (OS) were not significantly different between RIC-allo-HCT and auto-HCT, the risk of non-relapse mortality (NRM) was higher for both MSD-HCT and MUD-HCT, and for MUD-HCT, the chance of LFS and OS was lower.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Tamim Alsuliman, Nicolas Stocker, Elise Corre, Remy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty, Paul Coppo, Zora Marjanovic
Summary: Patients with high-risk lymphoma received R-COPADM and CYVE treatment, followed by ASCT if suitable. The study showed the efficacy and acceptable safety profile of this regimen, with a 87% overall survival rate and a 83% progression-free survival rate at 46 months of follow-up. These results suggest the potential benefit of this treatment approach for high-risk lymphoma patients.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Dai Chihara, Luuk Gras, Nienke Zinger, Nicolaus Kroeger, Jiri Mayer, Jakob Passweg, Regis Peffault de Latour, Jenny Byrne, William Krueger, Jan-Paul Bohn, Uwe Platzbecker, Igor Wolfgang Blau, Francesca Bonifazi, Grzegorz Helbig, Andrew McDonald, Martin Mistrik, Mohamad Mohty, Ron Ram, Jaime Sanz, Carlos Vallejo Llamas, Robert J. Kreitman, Patrick J. Hayden, Donal McLornan, Olivier Tournilhac, Michel van Gelder, Ibrahim Yakoub-Agha
Article
Hematology
Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schoenland, Nicolaus Kroeger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhaeuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schaefer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: In this registry-based study, the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) were compared. The study found that the total dose of total body irradiation (TBI) did not influence the survival outcomes for patients, regardless of whether they received a standard 12-Gray or lower 8-Gray dose.
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Helene Labussiere-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Peter Remenyi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty
Summary: Retrospective evaluation of transplant outcomes in adult AML patients undergoing allo-HCT in CR2 showed that post-transplant cyclophosphamide is an effective method for GVHD prophylaxis.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Frederic Baron, Annalisa Ruggeri, Christophe Peczynski, Myriam Labopin, Jean-Henri Bourhis, Mauricette Michallet, Patrice Chevallier, Jaime Sanz, Edouard Forcade, Riccardo Saccardi, Victoria Potter, Eliane Gluckman, Arnon Nagler, Mohamad Mohty
Summary: This study assessed the outcomes of patients who experienced graft failure after umbilical cord blood transplantation (CBT). It included a total of 87 patients and found that the cumulative incidence of relapse and nonrelapse mortality at 1-year was 35% and 37% respectively. Among patients who underwent salvage second transplantation, the 1-year and 2-year overall survival rates were 41% and 34% respectively. The study also identified complete remission and reduced-intensity conditioning as factors associated with better overall survival.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Tapani Ruutu, Christophe Peczynski, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty, Nicolaus Kroeger, Ivan Moiseev, Olaf Penack, Nina Salooja, Helene Schoemans, Rafael F. Duarte, Thomas Schroeder, Jakob Passweg, Gerald G. Wulf, Arnold Ganser, Simona Sica, Mutlu Arat, Urpu Salmenniemi, Annoek E. C. Broers, Jean Henri Bourhis, Alessandro Rambaldi, Johan Maertens, Kazimierz Halaburda, Tsila Zuckerman, Helene Labussiere-Wallet, Grzegorz Basak, Christian Koenecke, Zinaida Peric
Summary: The study investigated the incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers. It included 71 participating centers with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The findings showed a low incidence of VOD/SOS and a predominance of severe and very severe grades, indicating the importance of early diagnosis and treatment to improve outcomes.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Giorgia Battipaglia, Jarl E. Mooyaart, Ralf Meyer, Mohamad Mohty, Alicja Sadowska-Klasa, Oleg Goloshchapov, Franco Locatelli, Jan Styczynski, Jiri Pavlu, Jaroslaw Dybko, Gleb Bronin, Urpu Salmenniemi, Pavel Jindra, Jorinde D. Hoogenboom, Jurgen Kuball, Annalisa Ruggeri, Florent Malard
BONE MARROW TRANSPLANTATION
(2023)
Meeting Abstract
Oncology
Nirav N. Shah, Ian Flinn, Mi Kwon, Ulrich Jaeger, Javier Briones, Emmanuel Bachy, Didier Blaise, Nicolas Boissel, Koji Kato, Peter A. Riedell, Matthew J. Frigault, Leyla O. Shune, Takanori Teshima, Fabio Ciceri, Shaun A. Fleming, Silvia Ferrari, David Pearson, Jeanne Whalen, Aiesha Zia, Jaclyn Davis, Aisha Masood, Michael Dickinson, Pere Barba
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Yosr Hicheri, Cecile Castoldi, Raynier Devillier, Evelyne D'Incan, Sylvain Garciaz, Valerio Maisano, Colombe Saillard, Jerome Rey, Angela Granata, Samia Harbi, Faezeh Legrand, Sabine Furst, Didier Blaise, Norbert Vey
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Hematology
YC. Castoldi, Y. Hicheri, R. Devillier, MA. Hospital, E. D'Incan, S. Garciaz, V. Maisano, C. Saillard, J. Rey, A. Granata, S. Harbi, F. Legrand, S. Furst, D. Blaise, N. Vey
ANNALS OF HEMATOLOGY
(2023)
